Searched for
DIOVAN TABLETS
Dr Reddy's launches drug to treat high blood pressure, heart failure in US marketCiting IQVIA Health data, the company said the Diovan brand and generic market had US sales of approximately USD 150 million for the most r...- Dr. Reddy's inks pact with Singapore firm Prestige BioPharma to commercialise Trastuzumab biosimilar in select countriesHyderabad, Dec 9- Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two comp...
- With profit halved in Q2, it may take a while for Sun Pharma to come out of shadowsLower sales growth, supply constraints and currency movements in emerging markets dented second-quarter earnings at Sun Pharmaceutical Indu...
- Jubilant Life Sciences shares soar nearly 12 per centJubilant Life's stock soared 10.36 per cent to settle at Rs 159.85 on the BSE. In intra-day session, it advanced by 12.77 per cent to Rs 16...
- Jubilant Life gets ANDA approval for Valsartan tab; stock surges 7%The generic version of Novartis’ Diovan is used for treatment of hyper-tension. The current annualized US market size for the drugs is $2 b...
- Jubilant gets USFDA nod for generic anti-hypertensive tabletsThe drug firm has received final approval from the US health regulator for Valsartan tablets and plans to launch the product immediately.
- Aurobindo Pharma, Lupin and Jubilant Life Sciences get USFDA nod for hypertension drugThe tablets are indicated for treatment of hypertension and are the generic versions of Novartis Pharmaceuticals Corporation's Diovan table...
- Ranbaxy Q1 net loss narrows to Rs 185.92 croreRanbaxy's net loss in the April-June quarter was at Rs 186 crore ($30.94 million), compared with a loss of Rs 524 crore a year earlier.
- Ranbaxy gets FDA nod to sell generic Diovan tablets in USRanbaxy Laboratories, which has been facing regulatory hurdles in the US, has been allowed to sell generic Valsartan tablets.
- Lupin stock vaults to 52-week high on generic launch of Novartis' DiovanThe stock has gained 25% in the last one year – and has been one of the best performing stocks among the frontline pharma companies.
- Lupin gets USFDA nod for generic hypertension drugLupin today said it has received US health regulator's approval to market generic version of Novartis Pharmaceuticals Corp's Diovan HCT Tab...
- Aurobindo gets USFDA nod for Hydrochlorothiazide tabletsIn a statement, Aurobindo said the drug, a generic equivalent to Novartis Pharmaceuticals Corp's Diovan HCT Tablets, is ready for launch.
- Ranbaxy surprises street with Q4 loss of Rs 492 croreThe Gurgaon-based firm has provisioned Rs 186 crore to deal with the costs arising out of the product recall.
- Ranbaxy Laboratories shifts production of Lipitor generic to MohaliRanbaxy Laboratories has started shifting production of its generic version of the world's bestselling drug Lipitor from the US to its new ...
Load More
